HUTCHMED (NASDAQ:HCM) Stock Rating Lowered by StockNews.com

HUTCHMED ( NASDAQ:HCM – Get Free Report ) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Monday. Separately, The Goldman Sachs Group raised their price target on HUTCHMED from $17.

00 to $19.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Check Out Our Latest Analysis on HCM HUTCHMED Price Performance Institutional Inflows and Outflows Institutional investors and hedge funds have recently made changes to their positions in the business.



Russell Investments Group Ltd. lifted its position in shares of HUTCHMED by 70.5% during the 1st quarter.

Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock valued at $304,000 after acquiring an additional 7,515 shares during the period. Bellevue Group AG grew its stake in HUTCHMED by 2.

1% during the first quarter. Bellevue Group AG now owns 1,154,632 shares of the company’s stock worth $19,398,000 after buying an additional 23,521 shares in the last quarter. Hennion & Walsh Asset Management Inc.

grew its stake in HUTCHMED by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc.

now owns 61,887 shares of the company’s stock worth $1,060,000 after buying an additional 4,877 shares in the last quarter. Rhumbline Advisers raised its position in shares of HUTCHMED by 8.1% in the 2nd quarter.

Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after buying an additional 564 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of HUTCHMED by 74.8% during the 2nd quarter.

Renaissance Technologies LLC now owns 131,300 shares of the company’s stock worth $2,248,000 after acquiring an additional 56,200 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED ( Get Free Report ) HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. Featured Articles Five stocks we like better than HUTCHMED How to Read Stock Charts for Beginners Super Micro Computer Soars 28%: Is It Really Out of the Woods? Using the MarketBeat Stock Split Calculator Traders Are Flocking Back to Oil: What’s Fueling the Optimism What is the Hang Seng index? 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.

com's FREE daily email newsletter ..